Comparison of Bevacizumab and Aflibercept in Treatment of Diabetic Macular Edema

NCT07338097 · clinicaltrials.gov ↗

NA

Phase

ENROLLING_BY_INVITATION

Status

116

Enrollment

OTHER_GOV

Sponsor class

Conditions

Diabetic Macular Edema (DME)

Interventions

DRUG: Aflibercept (2.0 mg)
DRUG: Bevacizumab

Sponsor

CMH Multan Institute of Medical Sciences